A test-negative, case-control study across 14 hospitals in England has found that the RSV pre-F (Abrysvo) vaccine effectively reduced RSV-related hospital admissions in elderly. The findings published in The Lancet Infectious Diseases found the vaccines to be 82% effective in preventing hospital admission for any RSV-related respiratory illness and 87% effective against hospitalization for severe RSV in elderly.

The multicentre test-negative case-control study examined vaccine effectiveness in adults aged 75–79 years who were hospitalized for at least 24 hours with symptoms of acute respiratory infection (ARI) and tested using molecular diagnostic PCR swabs within 48 hours of admission.

In total, 1006 older adults were included in the analysis. Of these, 173 tested positive for RSV, wh

See Full Page